Bulletin
Investor Alert

April 9, 2021, 3:27 p.m. EDT

4 Top Biotech Stocks To Watch Today

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

Apr 09, 2021 (StockMarket.com via COMTEX) -- Could These Biotech Stocks Be The Best Stocks To Invest In Right Now?

You can't deny that biotech stocks have and continue to receive a whole lot of attention from investors now. Accordingly, this is because of the current pandemic where biotech companies are continuously hailed as heroes. In particular, key coronavirus vaccine makers in the industry such as Pfizer ( NYSE: PFE ) have become household names by now. No doubt, investors have likely been chasing after emerging biotech stocks now in hopes of finding the next big name. For the most part, I don't blame them. This is because biotech stocks are often the most active stocks on the stock market even now.

Take Novavax ( NASDAQ: NVAX ) and Ocugen ( NASDAQ: OCGN ) for example. Both companies are emerging names in the coronavirus vaccine market now. Despite not having a vaccine on the market, both are looking at gains of over 930% in the past year. However, with great gains also comes great risks. On one hand, positive updates on any phase of the drug development process could send a company's shares soaring. On the other hand, negative news could have the opposite effect.

Well, as we often say here at StockMarket.com , due diligence and proper research could help optimize your chances in this space. Having read till this point, you might be interested to invest in biotech stocks yourself. If that is the case, here are four in the spotlight now.

Best Biotech Stocks To Watch In April

Affimed NV

Affimed is a clinical-stage biotech company that is committed to giving patients back their innate ability to fight cancer. It does this by actualizing the untapped potential of the innate immune system. The company's proprietary ROCK platform enables a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors. The platform is versatile as it can be tailored to bispecific innate cell engagers to specific indications. AFMD stock currently trades at $9.93 as of 3:18 p.m. ET. Today, the stock rallied by over 23% upon the company's latest press release.

In detail, Affimed announced positive initial clinical data from an investigator-sponsored study. The study evaluates cord blood-derived natural killer cells pre-complexed with Affimed's innate cell engager AFM13. All four patients experienced significant disease reduction, with two complete responses and two partial responses. In the study, there were also no observed events of cytokine release syndrome or neurotoxicity syndrome.

This ultimately demonstrates encouraging initial safety and efficacy data. Additionally, these initial results would indicate that AFM13 may have the potential to help natural killer cells target and destroy cancer cells. Given the immense potential, the company will continue developing this treatment. With that being said, would you consider AFMD stock worth watching?

[Read More] Best Marijuana Stocks To Buy Today? 4 To Consider

Greenwich Lifesciences Inc.

Greenwich is a clinical-stage biopharmaceutical company focused on the development of its lead candidate, GP2. GP2 is an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GLSI stock has been up by over 50% since the start of the month and currently trades at $54.24 as of 3:16 p.m. ET. Investors seem to be responding to the company's press release on its GP2 clinical trial.

Basically, the company announced the abstract results of the final 5-year immune response data of its Phase IIb clinical trial. Its GP2 immunotherapy provides a robust immune response in metastatic breast cancer recurrences. In essence, potent immune response data support the previously reported clinical outcome of 0% metastatic breast cancer recurrences over 5 years of follow-up.

Impressively, the broad-based immune response also suggests that GP2 and Herceptin-based products may have the potential to treat other HER2 1-3+ expressing cancers. Time will tell if Greenwich can make the most out of this development. Given the exciting developments surrounding the company, will you consider adding GLSI stock to your watchlist?

1 2
This Story has 0 Comments
Be the first to comment

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.